BRIUMVI

TG Therapeutics, Inc.🇺🇸 United States

FDA Page

Effective Date: Jan 19, 2023
Approval ID: 3a77cd8c-811b-407c-9140-d0c5c26435c2
Products: 1 registered
Version: 5

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use BRIUMVI safely and effectively. See full prescribing information for BRIUMVI. BRIUMVI™ (ublituximab-xiiy) injection, for intravenous use Initial U.S. Approval: 2022

Quick Stats

Total Products1

Labelers2

Label Sections17

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.